Feb 18th 2025, Olymvax and Griffith University of Australia held a signing ceremony in Chengdu for their collaboration on the GAS project and contract manufacturing of GAS vaccine. The two parties established a joint laboratory for vaccine development in 2016 and have cooperated in the development of Group A Streptococcal vaccine (GAS vaccine) since then. This ceremony marks a significant milestone in the partnership between the two parties in the field of vaccine research and production.
The signing ceremony was attended and witnessed by the representatives from Griffith University, the Australian Consulate-General Chengdu, the Australian Trade and Investment Commission, and Queensland Trade and Investment office.
Mr. Fan Shaowen, Chairman and General Manager of Olymvax, delivered a welcome speech：GAS project has spanned several years. Through the close collaboration between Griffith University and our project team, as well as the strong support from the Australian Consulate-General Chengdu, and Trade and Investment office, we have overcome numerous challenges in the research and development, production coordination, and trans-national collaboration, successfully completing the production of GAS samples. Currently, the project has entered the final product testing phase, and all tasks are progressing smoothly. According to the current cooperation schedule, we are confident that we will achieve even more significant results in technology validation and market applications in the future. This will not only deepen the cooperation between China and Australia in the related fields but also bring more opportunities for technology innovation and business development to both sides. Once again, I would like to express our sincere gratitude to Griffith University, the Australian Consulate-General Chengdu, and Queensland Trade and Investment office for your trust and support! Thank you all!
Ms. Meaghan Shaw, Australian Consulate-General in Chengdu, addressed the conference: It is a privilege for me to support the partnership between the Griffith University, one of Australia’s leading universities, and Chengdu-based Olymvax. Australia’s health and biotech institutions and businesses are world-class, and they make a valuable contribution to China’s industry. Griffith University-Oymvax Strep A vaccine project is a good example where Australian and Chinese collaboration can save and change lives.I look forward to the growing Australia-southwestern China cooperation in the health sector, including biotech and vaccines research and development.
The presence of these distinguished guests underscores the importance of this collaboration and lays a solid foundation for Olymvax international development. This partnership not only deepens the collaboration between Olymvax and Griffith University in vaccine research but also signifies Olymvax's capability to undertake international contract manufacturing of vaccines. This achievement highlights Olymvax's technical expertise and represents a significant step towards its global expansion. Moving forward, Olymvax will continue to dedicate itself to vaccine research and production, contributing to global public health initiatives.
